Explore the words cloud of the EVA project. It provides you a very rough idea of what is the project "EVA" about.
The following table provides information about the project.
VENTINOVA MEDICAL BV
|Coordinator Country||Netherlands [NL]|
|Total cost||2˙313˙750 €|
|EC max contribution||1˙890˙000 € (82%)|
1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2. (PRIORITY 'Industrial leadership')
|Duration (year-month-day)||from 2015-11-01 to 2018-10-31|
Take a look of project's partnership.
|1||VENTINOVA MEDICAL BV||NL (EINDHOVEN)||coordinator||638˙750.00|
|2||UNIVERSITAETSKLINIKUM FREIBURG||DE (FREIBURG)||participant||551˙250.00|
|3||ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS||FR (PARIS)||participant||350˙000.00|
|4||UNITRON INNOTECH BV||NL (HENGELO)||participant||350˙000.00|
EVA - Expiratory Ventilation Assistance – , or expiration by suction, is an innovative method to mechanically ventilate patients and is a key step in ventilation towards less-invasive, tailored and improved patient care as it enables: 1. full ventilation through a thin catheter instead of a thick tube 2. low and – if needed – negative pressures in the lungs promoting blood circulation 3. controlling the expiration, reducing sheer stress, which may prevent lung injury and improve patient outcome.
The EVA technology has already been on the market for some years in its most basic form: the manual, disposable emergency ventilator Ventrain®. Since market launch in 2011, Ventrain® is now being sold by 16 distributors in over 20 countries. Ventinova’s flagship is the “EVA device”: a fully automated ventilator based on EVA technology meeting the emerging needs of less invasive, tailored and improved patient care. First is focused on the large markets of elective surgical procedures and emergency care (€ 400 M, globally) and in 2nd generation on ICU-ventilation (€ 500 M, globally), before becoming ‘standard care’ (€ 4.6 billion, globally). The device, currently at TRL6, is still in development and CE marking is expected in Q3 2016. Next to marketing activities, such as organizing workshops and training sessions, and careful selection and support of distributors, penetration of the conservative medical market should be ensured by demonstration of better and tailored patient care using EVA ventilation in pre-clinical studies and controlled clinical trials. These are to be designed and executed in close collaboration with Key Opinion Leaders of established and world leading academic medical centers.
The described technology and products are protected by 5 patent families and design and brand registrations. The products are manufactured in The Netherlands and a dedicated catheter in Ireland. After CE marking, large non-EU markets are to be entered (e.g. USA, China, Russia).
Work performed, outcomes and results: advancements report(s)
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EVA" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "EVA" are provided by the European Opendata Portal: CORDIS opendata.
Tomographic 3D Ultrasound for Safe and More Cost Effective Vascular Diagnostics andTreatment PlanningRead More
Automatic non-destructive recognition of used printing techniques on substratesRead More
Market Uptake of Sustainable and Competitive Carbons for Energy StorageRead More